LACTOLOGY FOUNDATION

Osteoarthritis: Pathophysiology, Clinical Spectrum, Diagnostic Paradigms, and Evidence-Based Therapeutic Strategies

Abstract & Epidemiological Landscape

Osteoarthritis (OA), historically referred to as degenerative joint disease, hypertrophic arthritis, or osteoarthrosis, represents the most common form of joint pathology and a primary driver of physical disability and loss of independence in aging populations. The disorder is pathologically defined by the progressive degeneration of articular hyaline cartilage, accompanied by reactive structural changes in subchondral bone, periarticular soft tissue remodeling, and low-grade synovial inflammation.

Quantifying the global burden of osteoarthritis is complicated by the systemic discordance between asymptomatic radiologic abnormalities and clinically overt symptoms. Population-based radiographic surveys indicate that asymptomatic structural features of OA are present in approximately 30% of hands, 21% of feet, and 3% of knees and hips across the general adult population. Among individuals older than 65 years, radiographic manifestations expand dramatically, reaching approximately 33% in the knee and approaching nearly 100% in the small joints of the hand. However, symptomatic disease—defined by the co-occurrence of structural alterations and localized pain or functional limitation—affects roughly 6% of adults for knee OA and 4% for hip OA between the ages of 30 and 60 years. Beyond 60 years of age, the prevalence of symptomatic osteoarthritis rises to 17% in males and 30% in females.

Sex distribution and demographic patterns reveal complex underlying biological and environmental susceptibility factors. While men and women exhibit equivalent overall prevalence rates in middle age, women over 50 years manifest a significantly higher incidence of disease, particularly within the interphalangeal joints of the hands. Geographic and ethnic variations further emphasize genetic and occupational interactions: hip osteoarthritis demonstrates a markedly lower prevalence in Japanese, Saudi Arabian, Chinese, and native African populations compared to Caucasian cohorts of European descent. Conversely, knee osteoarthritis is disproportionately prevalent in African-American women and urban Chinese populations, reflecting variations in joint geometry, body composition, and physical activity profiles.

Etiology, Risk Factors, and Pathogenetic Drivers

Osteoarthritis is categorized into primary (idiopathic) and secondary forms based on the presence of identifiable antecedent structural, traumatic, or metabolic insults. Primary osteoarthritis develops without an explicit underlying systemic disease or acute mechanical index event. It may manifest as monoarticular or oligoarticular disease, or progress into primary generalized osteoarthritis involving multiple joint regions. A distinct subset, designated as erosive osteoarthritis, predominantly targets the interphalangeal joints of postmenopausal women and is marked by polyarticular subchondral erosions and localized inflammatory flares.

Secondary osteoarthritis results from identifiable disorders that disrupt articular cartilage integrity through mechanical incongruity, metabolic deposition, or enzymatic degradation.

Risk factors for primary osteoarthritis involve an intricate interplay between systemic vulnerability and localized biomechanical stress. Age represents the single strongest risk factor for both radiographic and clinically symptomatic disease. Although age-related senescent alterations in chondrocyte synthetic function are distinct from the primary pathological cascade of OA, they impair the intrinsic capacity of cartilage to repair low-grade matrix micro-damage.

Obesity exerts both systemic metabolic influence and direct biomechanical overload, particularly upon weight-bearing joints. Each 8 kg increase in body mass correlates with a 70% increase in the risk of developing symptomatic knee osteoarthritis in later life. This risk is amplified in individuals with varus joint malalignment, creating a localized feedback loop that accelerates compartmental structural decline. Furthermore, elevated systemic levels of adipokines, such as leptin, present in obese individuals, diffuse into the synovial compartment and upregulate pro-inflammatory and catabolic mediator release from chondrocytes.

The relationship between systemic bone mineral density (BMD) and osteoarthritis highlights a biomechanical trade-off. Women with high systemic BMD display a lower incidence of osteoporotic fractures but a significantly higher prevalence of osteoarthritis. Dense subchondral bone possesses diminished shock-absorbing compliance, transferring peak mechanical shear stresses directly into the overlying hyaline cartilage matrix. Paradoxically, localized bone mineral loss or systemic Vitamin D deficiency accelerates structural disease progression once osteoarthritis is established, demonstrating that subchondral structural integrity is required to maintain cartilage stability.

Repetitive mechanical impact loading drives rapid degenerative alterations in articular cartilage. Occupations requiring habitual knee bending, squatting, or heavy lifting markedly increase the risk of knee and hip OA. Neuromuscular deficits, including diminished quadriceps muscular strength and impaired joint proprioception, reduce the dynamic stabilization of weight-bearing joints, subjecting articular surfaces to abnormal kinematic forces even in non-painful early disease stages.

Heritable factors account for 40% to 60% of the risk for hand, hip, and spine osteoarthritis. Genetic studies demonstrate linkage to structural collagen gene polymorphisms, such as mutations in the type II procollagen gene (COL2A1), as well as single-nucleotide polymorphisms in the Vitamin D receptor (VDR) gene and the estrogen receptor alpha (ESR1) gene. Mutations in the HFE gene, responsible for hemochromatosis, show a strong association with hand OA in older cohorts. Subclinical structural dysplasias of the acetabulum further contribute to hip OA susceptibility, confirming the polygenic architecture of primary osteoarthritis.

Macromolecular Structure and Pathophysiology of Articular Cartilage

Healthy articular cartilage is an avascular, aneural, and dynamic connective tissue designed to withstand repetitive compressive loads and minimize frictional wear across diarthrodial joints. It consists of specialized cells—chondrocytes—embedded within a vast extracellular matrix (ECM) dominated by type II collagen, proteoglycans, non-collagenous proteins, and water.

Type II collagen forms a structured three-dimensional fibrillar network. In the superficial zone, collagen fibers are oriented parallel to the articular surface, acting as a shear-resistant membrane. In deeper zones, fibers transition to a perpendicular orientation, anchoring the uncalcified cartilage matrix across the tidemark to calcified cartilage and the subchondral bone plate.

The proteoglycan constituent is dominated by aggrecan, a high-molecular-weight monomer comprising a central core protein attached to hydrophilic glycosaminoglycan (GAG) side chains of chondroitin sulfate and keratan sulfate. Via specialized link proteins, hundreds of aggrecan monomers aggregate along central filaments of hyaluronate, generating macromolecular structures exceeding $10^8$ Daltons. The high density of fixed negative electrical charges on GAG chains attracts mobile cations, drawing water into the ECM via osmotic pressure. This creates an internal swelling pressure restrained by the tensile strength of the collagen network, conferring compressive resilience to the joint tissue.

In osteoarthritic cartilage, matrix synthesis and breakdown become dysregulated, driving structural disruption across all cartilage zones. The earliest biochemical event is an increase in total matrix water content accompanied by structural disorganization of the superficial collagen framework. Initial chondrocyte hyper-reactivity leads to cellular proliferation and clustering (cloning), alongside transient increases in collagen and proteoglycan synthesis.

As catabolic signals dominate, chondrocytes overexpress proteolytic enzymes, including matrix metalloproteinases (MMP-13, MMP-3), collagenases, gelatinases, hyaluronidases, and aggrecanases (ADAMTS-4 and ADAMTS-5). Concurrently, endogenous enzymatic suppressors, such as tissue inhibitors of metalloproteinases (TIMPs), are degraded or downregulated. Pro-inflammatory mediators—including interleukin-1 beta (IL-1$\beta$), tumor necrosis factor-alpha (TNF-$\alpha$), inducible nitric oxide synthase (iNOS), and prostaglandins—suppress anabolic matrix synthesis and accelerate enzymatic digestion.

Matrix degradation leads to surface fibrillation, vertical fissuring, deep matrix erosion, and tidemark duplication. Vascular invasion from the underlying subchondral bone introduces capillary networks into the calcified cartilage zone, promoting abnormal osteochondral remodeling and calcification. shed matrix breakdown fragments enter the synovial fluid, triggering low-grade synovitis. Synovial inflammation amplifies local cytokine production, establishing a feed-forward loop that drives progressive cartilage degradation, subchondral sclerosis, osteophyte formation, and bone marrow edema (BME).

Clinical Manifestations and Phenotypic Variations

The clinical presentation of osteoarthritis is defined by joint pain, transient morning stiffness, movement-induced crepitus, periarticular tenderness, bony enlargement, and progressive loss of physical function. Pain is characteristically insidious, localized to affected joints, exacerbated by weight-bearing activity, and relieved by rest. As structural degeneration advances, pain may occur at rest or interrupt sleep. Morning joint stiffness in OA typically lasts less than 30 minutes, distinguishing it from prolonged stiffness observed in systemic inflammatory arthropathies. Patients frequently experience "gelling"—transient joint stiffness following static postures. Physical examination reveals bony enlargement, movement crepitus, reduced range of motion, dynamic instability, and localized effusions with minimal soft-tissue erythema or warmth.

Osteoarthritis demonstrates specific phenotypic distributions across anatomical joint groups:

• Hand Osteoarthritis: Predominantly involves the distal interphalangeal (DIP) joints, proximal interphalangeal (PIP) joints, and the first carpometacarpal (1st CMC) joint at the thumb base. Bony hypertrophy yields Heberden nodes at the DIP joints and Bouchard nodes at the PIP joints. Individual joints may undergo episodic inflammatory phases marked by local swelling, pain, and dorsal mucous cyst formation before settling into indolent bony enlargements. Involvement of the 1st CMC joint causes thumb base subluxation, local pain, and loss of pinch strength. Erosive hand OA is characterized by acute inflammatory flares, severe pain, marked functional loss, and classic radiographic central erosions.
• Knee Osteoarthritis: Involves the medial tibiofemoral, lateral tibiofemoral, or patellofemoral compartments. Patients report pain exacerbated by weight-bearing activities such as stair negotiation or standing from a seated position. Examination reveals crepitus, joint line tenderness, restriction of motion, variable effusions, and muscle atrophy. Progressive medial compartment collapse induces varus malalignment, whereas lateral loss results in valgus angulation. Patellofemoral disease presents with anterior knee pain and crepitus during deep flexion.
• Hip Osteoarthritis: Presents as deep groin or anterior thigh pain that may radiate down the ipsilateral extremity to the knee, occasionally confounding clinical localized diagnosis. Patients display restricted hip internal rotation and abduction, accompanied by an antalgic gait. Functional impairment manifests as difficulty with daily tasks, such as putting on socks or entering vehicles.
• Spinal Osteoarthritis (Spondylosis): Targets the intervertebral disc interfaces and posterior apophyseal (facet) joints of the cervical and lumbar regions. Degenerative disc height loss and facet joint osteophytosis can cause localized axial pain, radiculopathy from foraminal narrowing, or central spinal stenosis. Lumbar spinal stenosis produces neurogenic claudication—lower extremity weakness and radicular pain precipitated by walking or spinal extension and relieved by lumbar flexion. Diffuse Idiopathic Skeletal Hyperostosis (DISH) manifests in the thoracic spine as prominent bridging osteophytes with reduced axial mobility but minimal pain.

Diagnostic Evaluation, Imaging Modalities, and Biomarkers

The diagnosis of osteoarthritis relies on a clinical evaluation supported by structural imaging. Standard laboratory evaluations—including complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum uric acid, and autoimmune serologies—are within reference ranges in primary OA unless concurrent systemic conditions exist. Synovial fluid aspiration confirms a non-inflammatory profile, characterized by clear fluid, high viscosity, and a white blood cell count below 2,000 cells/$\text{mm}^3$ with a predominance of mononuclear cells. The presence of non-birefringent basic calcium phosphate (BCP) microcrystals is common in typical OA fluid, whereas birefringent calcium pyrophosphate dihydrate (CPPD) crystals signal concomitant crystal arthropathy.

Plain conventional radiography remains the primary imaging modality for confirming structural OA. Characteristic radiographic features include asymmetrical joint space narrowing, subchondral bone sclerosis, subchondral cysts, and marginal osteophytes. Radiographs of weight-bearing joints (knees and hips) must be performed in a standing posture; recumbent imaging can underestimate joint space loss due to absence of gravitational load. In hand OA, central subchondral erosions in interphalangeal joints produce a distinct "gull-wing" appearance that differentiates erosive OA from the marginal erosions of rheumatoid arthritis.

Magnetic Resonance Imaging (MRI) offers soft tissue visualization, allowing for non-invasive assessment of uncalcified cartilage degradation, meniscal integrity, synovial volume, and subchondral bone pathology. Fat-suppressed MRI sequences (such as Short Tau Inversion Recovery [STIR]) detect subchondral bone marrow edema (BME) as areas of high signal intensity. Subchondral BME correlates directly with localized weight-bearing pain and serves as a predictor of structural cartilage loss over time.

Classification criteria established by EULAR integrate clinical features, morning stiffness duration, osteophytosis, and joint space narrowing to standardize patient characterization in hand, knee, and hip OA studies.

Differential Diagnosis

Given the high background prevalence of asymptomatic radiographic alterations in older adults, clinicians must systematically exclude non-osteoarthritic pathology before attributing musculoskeletal complaints to degenerative cartilage changes.

Comprehensive Evidence-Based Management Strategies

Because no approved disease-modifying osteoarthritis drugs (DMOADs) currently exist to reverse structural cartilage loss, contemporary clinical guidelines—including recommendations from the American College of Rheumatology (ACR), EULAR, and OARSI—focus on reducing pain, optimizing joint function, and preventing disability through tailored multimodal interventions.

Non-Pharmacological Modalities

Non-pharmacological strategies constitute the core foundation of osteoarthritis management across all joint sites. Structured exercise programs—encompassing targeted neuromuscular strengthening, joint range-of-motion exercises, and low-impact aerobic conditioning (e.g., walking, aquatic exercise)—significantly reduce joint pain and functional decline. Targeted quadriceps strengthening reduces mechanical shear stress across the patellofemoral and tibiofemoral compartments, addressing functional deficits in knee OA.

Dietary weight management is strongly recommended for overweight or obese patients with knee or hip OA. Reductions in body weight decrease weight-bearing joint loads and lower systemic circulating pro-inflammatory adipokines.

Biomechanical loading can be modified using custom hand orthoses for first CMC joint OA, unloader knee bracing for isolated tibiofemoral compartment disease, lateral wedged insoles, patellar taping, and contralateral walking canes. Self-management education programs, cognitive behavioral therapy, and Tai Chi are strongly or conditionally recommended across major international management guidelines.

Pharmacological Interventions and Safety Considerations

Pharmacological therapy focuses primarily on pain management, balancing analgesic efficacy against patient-specific gastrointestinal, renal, and cardiovascular safety profiles.

Topical non-steroidal anti-inflammatory drugs (NSAIDs), such as topical diclofenac, are recommended as first-line therapy for knee and hand OA. Topical formulations deliver local anti-inflammatory efficacy comparable to oral NSAIDs while minimizing systemic absorption and associated adverse events.

Systemic oral NSAIDs (including non-selective agents and COX-2 selective inhibitors) demonstrate superior pain relief compared to acetaminophen. However, non-selective oral NSAIDs carry dose-dependent risks of upper gastrointestinal ulceration, acute renal insufficiency, blood pressure elevation, and heart failure exacerbation. Gastroprotective strategies require co-prescribing proton pump inhibitors (PPIs) or misoprostol alongside non-selective NSAIDs, or substituting COX-2 selective inhibitors (coxibs such as celecoxib).

Cardiovascular risk remains an important consideration when prescribing COX-2 inhibitors and traditional NSAIDs. The withdrawal of rofecoxib from global markets followed data from the APPROVe trial, which demonstrated a two-fold increase in thrombotic cardiovascular events (1.5% vs 0.7% over 3 years) compared to placebo. Consequently, major management guidelines recommend avoiding oral NSAIDs of any class in patients with established cardiovascular disease, previous myocardial infarction, or chronic renal impairment.

Acetaminophen (paracetamol) was historically utilized as first-line monotherapy up to 4,000 mg/day. Recent meta-analyses demonstrate minimal clinical efficacy over placebo for OA pain, leading contemporary OARSI and ACR guidelines to conditionally recommend against its routine use. Regular acetaminophen use also warrants caution regarding potential hepatotoxicity, particularly in individuals who consume alcohol.

Tramadol, a centrally acting analgesic that inhibits norepinephrine and serotonin reuptake alongside mu-opioid receptor agonism, is recommended as a secondary option when NSAIDs are contraindicated or ineffective. Systemic or transdermal traditional opioids are strongly discouraged due to high risks of dependence, tolerance, fall-related injuries, and lack of long-term functional benefit.

Complementary and Phytotherapeutic Agents

Patients frequently utilize complementary nutraceuticals and phytotherapeutic formulations to manage joint symptoms. While evidence for structural cartilage protection remains unproven, several agents demonstrate low-grade anti-inflammatory activity. Clinicians must remain aware of potential drug-herb interactions when evaluating overall treatment plans.

Intra-Articular Injections and Surgical Interventions

Intra-articular corticosteroid injections provide short-term relief during acute inflammatory flares accompanied by joint effusion. Repeated intra-articular steroid injections every 3 months demonstrate safety and symptom relief in selected knee OA cohorts over extended periods. Intra-articular hyaluronic acid injections (viscosupplementation) aim to restore synovial fluid viscoelasticity; however, mixed meta-analytic data have led to variable recommendations across ACR, EULAR, and OARSI panels.

Surgical consultation is indicated for advanced, end-stage osteoarthritis characterized by refractory pain and severe functional disability despite maximal conservative therapy. Total joint replacement (arthroplasty) of the hip or knee yields predictable pain relief, improved range of motion, and functional restoration. Joint replacement complications—such as aseptic loosening, periprosthetic infection, or deep vein thrombosis—are relatively uncommon. High tibial wedge osteotomy is reserved for younger, active individuals with unicompartmental knee OA to realign weight-bearing axes and offload damaged articular cartilage.

Arthroscopic lavage and debridement demonstrate no superior benefit over sham surgical controls in randomized trials (e.g., Moseley et al.) and are restricted to joints presenting with true mechanical locking from unstable meniscal tears or loose osteochondral fragments.

Prognosis and Future Directions

Osteoarthritis is a slowly progressive condition with a variable long-term prognosis. Radiographically, structural changes within affected joints remain stable or worsen gradually over 5- to 15-year intervals. Clinical symptoms often fluctuate, experiencing unexplained long-term remissions. Hand OA frequently stabilizes and becomes less painful following spontaneous fusion of interphalangeal joints.

Investigational efforts are focused on identifying disease-modifying osteoarthritis drugs (DMOADs) that target specific pathological pathways. These include sub-antimicrobial matrix metalloproteinase inhibitors (e.g., doxycycline), selective Wnt pathway inhibitors (e.g., lorecivivint), recombinant human growth factors (e.g., sprifermin), targeted cytokine inhibitors, gene therapy vectors for localized intra-articular IL-1 receptor antagonism, and autologous mesenchymal stem cell transplantation for localized cartilage restoration.

Optimal management continues to rely on early diagnosis, structural risk stratification, patient education, weight control, tailored exercise, and judicious pharmacological and surgical interventions.